Tenderwize
Zurück zur Suche

Open-House Discount Contracts for Infliximab (Subcutaneous Injection)

Techniker Krankenkasse·Hamburg, Germany·Deadline May 30, 2028 · 645 days left·Open·Supplies
Registrieren zum SpeichernOpen documents
Structured notice only
Originaltitel der Bekanntmachung

Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2026-10 - Infliximab (Darreichungsform zur subkutanen Injektion)

40/100

Opportunity Score

Needs reviewLow complexity
SuppliesOpen
Warum diese Bewertung?

Chance

40 / 100

Komplexität

30 / 100

Risikofaktoren

No estimated contract value, framework maximum value, or budget provided. Revenue potential is unknown.

Contract ends automatically upon patent expiry or loss of market exclusivity. Could be terminated earlier than the max...

Tiefe Portfolioanalyse

Tiefe Analyse der Unternehmenspassung

Verwendet:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Überblick

Moderate opportunity

Wichtige Fakten

  • Supplies contract
  • 1 lot
  • Duration until May 2028
  • Conclusion of discount contracts for Infliximab (subcutaneous injection) with multiple pharmaceutical entrepreneurs.
  • Uniform contract terms; no individual negotiations.
Vollständige Zusammenfassung anzeigen

Open-House procedure for discount contracts (Rabattverträge) under § 130a Abs. 8 SGB V for the active substance Infliximab (subcutaneous injection). No competitive selection; any qualified pharmaceutical entrepreneur can join. No estimated value provided. The lead buyer is Techniker Krankenkasse, with several other German statutory health insurance funds. The contract term is up to 24 months starting June 1, 2026, ending May 31, 2028. Participation is open throughout the contract term. No procurement documents were analyzed.

Risiken

No estimated contract value, framework maximum value, or budget provided. Revenue potential is unknown.

Contract ends automatically upon patent expiry or loss of market exclusivity. Could be terminated earlier than the max...

Analyse kann unvollständig sein

Nur ein Teil der Vergabeunterlagen wurde analysiert. Weitere Anforderungen, Zertifikate oder Einreichungsdokumente können in den übrigen Unterlagen enthalten sein.

Wichtige Anforderungen

Technical

  • Must be a pharmaceutical entrepreneur as defined by § 4 Abs. 18 AMG.
  • Must hold a valid marketing authorization for the product or be entitled to place the product on the market.

Administrative

  • Must provide a self-declaration on authorization and company (Anlage 4).

Anforderungen können unvollständig sein.

Auftraggeber

Ort

Hamburg, DEU

Kennung

992-80116-93

Tätigkeit

Health

Lose (1)

LOT-0001

Open-House Discount Contracts for Infliximab (Subcutaneous Injection)

Conclusion of discount contracts for the active substance Infliximab (subcutaneous injection) with any eligible pharmaceutical entrepreneur under an open-house model. No exclusivity; uniform conditions apply.

SuppliesEU fundedElectronic submission

Ort

DE600, Germany

Dauer

May 2026 - May 2028

Kategorie

Pharmaceutical products

Frist

Deadline May 30, 2028

Vergabedetails

Veröffentlichungsdatum
19 Apr 2026
Sprachen
German

Referenzmetadaten

Rechtsgrundlage
32014L0024

Referenz-IDs

Ausschreibungs-ID
266368-2026

Dokumente (1)

Vergabedokument 1

Ähnliche Ausschreibungen

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3